Clinical Practice

• By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of infection testing, ultimately facilitating better patient care and outcomes.
• Advanced molecular testing revolutionizes the diagnosis and management of infections, as it delivers rapid and precise results, ultimately enabling quicker initiation of appropriate treatment interventions.
• “We are excited to integrate molecular testing capabilities into our infection diagnosis protocols,” states Cyndi Shook, Senior Vice President of Clinical Operations at Amedisys.
• For more information about Amedisys Home Health and its advanced molecular testing capabilities, please visit www.amedisys.com.

• One review study published in August 2021 estimated that the global prevalence of children and adolescents with depression and anxiety had doubled since the start of the pandemic.
• In a new study, we found that GPs in the UK recorded a large rise in eating disorder diagnoses and self-harm episodes among teenage girls in the first two years of the pandemic.

Comparing predictions and observed case numbers

• We included over 9 million patients aged ten to 24 (both males and females) from 1,881 general practices across the UK.
• We calculated the monthly incidence rates of eating disorder diagnoses and self-harm episodes from January 2010 through to March 2022.
• We then compared the rates actually observed in March 2020 until March 2022 with these predictions.
• There was little difference between observed and expected incidence for the other age groups.

Limitations and possible explanations

• However, it’s also possible that cases of self-harm not coming to the attention of services might have exhibited a different pattern.
• Previous studies have reported increased hospital admissions and presentations to emergency departments for self-harm and symptoms of eating disorders among teenage girls during the COVID pandemic.
• These include social isolation, anxiety resulting from changing routines, disruption to education, unhealthy social media influences, and increased awareness of mental health difficulties.

What next?

• Early identification of mental health difficulties in children and young people by primary care clinicians (including GPs, nurses and psychologists) is extremely important, as this facilitates timely access to treatment.
• Potential barriers to help-seeking, including fear of stigma and concerns about long waiting lists to access services, need to be tackled.

• This press release does not include all the information needed to use Somryst safely and effectively.
• Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs).
• For example, statements that indicate clinical utility and durable economic benefit of patients using Somryst will improve are forward-looking statements.
• Real-World Evaluation of Clinical Response and Long-Term Healthcare Resource Utilization Patterns Following Treatment with a Digital Therapeutic for Chronic Insomnia.

• FAYETTEVILLE, N.C., May 17, 2022 /PRNewswire/ -- Duke T. Matsuyama is being recognized by Continental Who's Who as a Top Anesthesiologist in the Medical field and in acknowledgment of his work at Cumberland Anesthesia Associates.
• Duke T. Matsuyama is a dedicated Anesthesiologist with a background in the United States Navy and Clinical Practice.
• To begin his college education, Dr. Matsuyama earned a Bachelor of Arts degree in Biological Sciences from California State University, Fullerton, in 1997.
• Dr. Matsuyama completed an internship in Osteopathic Medicine and an Anesthesiology residency at Grandview Hospital and Medical Center in Dayton, Ohio.